{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Triple+Negative+Breast+Cancers", "query": { "condition": "Metastatic Triple Negative Breast Cancers" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 364, "total_pages": 37, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Triple+Negative+Breast+Cancers&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T01:10:25.815Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03454451", "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Cancer", "Colorectal Cancer", "Triple Negative Breast Cancer", "Cervical Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Endometrial Cancer", "Sarcoma", "Squamous Cell Carcinoma of the Head and Neck", "Bladder Cancer", "Metastatic Castration Resistant Prostate Cancer", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "CPI-006", "type": "DRUG" }, { "name": "CPI-006 + ciforadenant", "type": "DRUG" }, { "name": "CPI-006 + pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-04-25", "completion_date": "2023-02-19", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454451" }, { "nct_id": "NCT05570253", "title": "A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Eribulin", "type": "DRUG" }, { "name": "SDX-7320", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2022-10-03", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 10, "location_summary": "Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05570253" }, { "nct_id": "NCT05673200", "title": "Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2023-09-25", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Costa Mesa, California • Orange, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05673200" }, { "nct_id": "NCT03838367", "title": "Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "350 mg leronlimab", "type": "DRUG" }, { "name": "525 mg leronlimab", "type": "DRUG" }, { "name": "700 mg leronlimab", "type": "DRUG" }, { "name": "AUC 5 Carboplatin", "type": "DRUG" }, { "name": "Maximum Tolerated Dose (MTD) of leronlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytoDyn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2019-04-22", "completion_date": "2022-09-16", "has_results": true, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 2, "location_summary": "San Francisco, California • Chicago, Illinois", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03838367" }, { "nct_id": "NCT06959537", "title": "A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Axatilimab (SNDX-6352)", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-08-13", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06959537" }, { "nct_id": "NCT05086731", "title": "Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Localized Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2021-10-22", "completion_date": "2024-03-06", "has_results": false, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086731" }, { "nct_id": "NCT03291938", "title": "IACS-010759 in Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Negative", "HER2/Neu Negative", "Metastatic Malignant Solid Neoplasm", "Pancreatic Ductal Adenocarcinoma", "Progesterone Receptor Negative", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Lymphoma", "Refractory Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Oxidative Phosphorylation Inhibitor IACS-010759", "type": "DRUG" }, { "name": "Pharmacodynamic Study", "type": "OTHER" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-11-13", "completion_date": "2020-11-23", "has_results": false, "last_update_posted_date": "2020-11-24", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291938" }, { "nct_id": "NCT04445844", "title": "INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Locally Advanced Breast Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "Pelareorep", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Mridula George, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2020-07-13", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • Columbus, Ohio", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04445844" }, { "nct_id": "NCT01745367", "title": "Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Tivozanib Hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2012-11", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2020-10-27", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01745367" }, { "nct_id": "NCT03800836", "title": "A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "AC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2018-02-13", "completion_date": "2022-03-16", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-06-26T01:10:25.815Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03800836" } ] }